1[1]KaySR,SandyKR.Interpretation of the positive-negative distinction.In:Kay SR,ed.Positive and negativesyndrom incshizophrenia:Assessment and research[M].New York:Brunner\mazel,1991:194-213.
4Yasuo O,Seiji S,Nobuyuki K,et al.Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-piperaziny)bytoxy]-3,4-dihtoxy]-3,4-dihydro-2(1H)-quinolinone Derivatives[J].J Med Chem ,1998,41:658-667.
5李兴法.阿立哌唑的制备新方法[P].中国专利:14500056A,2003-10-22.
6Yasuhiro T,Koichi S,Takao N,et al.Synthetic study on the unique dimeric arylpiperazine: access to the minor contaminant of aripiprazole [J].Bioorg Med Chem Lett,2003,13:65-68.
7舒良，中华神经精神科杂志，1987年，20卷，43页
8Lawler CP,Prioleau C,Lewis MM,et al.Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes.Neuropsychopharmacolgy,1999,20(6):612～627.
9Goodnick PJ,Jerry JM.Aripiprazole:profile on efficacy and safety.Expert Opin Pharmacother,2002,3(12):1773～1781.
